Latest News
ImmunityBio, Inc.
- ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
- Immunitybio Announces Database Lock For Registrational Trial Of Locally Delivered, Chemotherapy-Free Anktiva® Plus Bcg In Bcg-Naïve Non-Muscle Invasive Bladder Cancer
- ImmunityBio completes database lock for bladder cancer trial By Investing.com
- Form 144 IMMUNITYBIO INC For: 17 October By Investing.com
- Recon: ImmunityBio’s Anktiva clears FDA expansion in bladder cancer; “Gross contamination” found at Chinese site manufacturing GLP-1 components
- ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion
- ImmunityBio Stock Climbs Thursday: What's Going On?
- ImmunityBio bags elusive label extension for Anktiva
- FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash
- Why Is ImmunityBio Stock Gaining Wednesday?
- Immunitybio Inc Stock (IBRX) Moved Up by 9.64% on Oct 2: What Investors Need To Know
- ImmunityBio Stock Jumps: What's Going On?
Headlines from the last 30 days, linking to the original publishers. See all market news →